Home > Insider Trading > Filing (0001628280-19-004178)

Filing Details

Accession Number:: 0001628280-19-004178
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-10 21:58:47
Reporting Period:: 2019-04-08

Accepted Time:: 2019-04-10 21:58:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1397702	Silk Road Medical Inc	SILK	Surgical & Medical Instruments & Apparatus (3841)	208777622

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1414561	Warburg Pincus X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414564	L.p. Gp X Pincus Warburg	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414565	Warburg Pincus Private Equity X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1451560	Warburg Pincus X Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1621224	Warburg Pincus Partners Gp Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1621242	Warburg Pincus Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1621874	Wpp Gp Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1770767	Wp X Finance, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1770772	Wpx Gp, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-08	13,079,728	$0.00	13,099,629	No	4	C	Direct
Common Stock	Disposition	2019-04-08	900,000	$20.00	12,199,629	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2019-04-08	5,637,492	$0.00	5,637,492	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-04-08	5,904,180	$0.00	5,904,180	$0.00
Common Stock	Series C Preferred Stock Warrant (Right to buy)	Disposition	2019-04-08	1,071,902	$0.00	1,071,902	$6.11
Common Stock	Series C Preferred Stock Warrant (Right to buy)	Disposition	2019-04-08	1,074,072	$0.00	1,074,072	$6.11
Common Stock	Series C Preferred Stock Warrant (Right to buy)	Disposition	2019-04-08	34,291	$0.00	34,291	$6.11
Common Stock	Series C Preferred Stock Warrant (Right to buy)	Disposition	2019-04-08	34,361	$0.00	34,361	$6.11
Common Stock	Series C Preferred Stock	Acquisiton	2019-04-08	2,145,974	$0.00	2,145,974	$0.00
Common Stock	Series C Preferred Stock	Acquisiton	2019-04-08	68,652	$0.00	68,652	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-04-08	655,596	$0.00	655,596	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-04-08	20,974	$0.00	20,974	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-04-08	1,538,056	$0.00	1,538,056	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Direct
0		No	4	C	Direct
0	2022-08-07	No	4	X	Direct
0	2023-10-13	No	4	X	Direct
0	2022-08-07	No	4	X	Direct
0	2023-10-13	No	4	X	Direct
2,145,974		No	4	X	Direct
68,652		No	4	X	Direct
1,490,378		No	4	J	Direct
47,678		No	4	J	Direct
0		No	4	C	Direct

Footnotes

The Series B Preferred Stock and Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
12,693,546 of these shares are held by WP X Finance, L.P. ("WP X Finance") and 406,083 of these shares are held by Warburg Pincus X Partners, L.P. ("WPXP"). The total of 13,099,629 shares beneficially owned is comprised of (i) 19,901 shares of Common Stock held prior to the date hereof (ii) 5,637,492 shares of Common Stock issued upon conversion of Series B Preferred Stock held prior to the date hereof, (iii) 5,904,180 shares of Common Stock issued upon conversion of Series C Preferred Stock held prior to the date hereof, and (iv) 1,538,056 shares of Common Stock issued upon conversion of Series C Preferred Stock issued pursuant to the net exercise of warrants, as detailed in footnotes (9), (12), (13) and (15).
WPX GP, L.P., a Delaware limited partnership ("WPX GP"), is the managing general partner of WP X Finance. Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), is the general partner of WPX GP. Warburg Pincus X, L.P., a Delaware limited partnership ("WPX LP"), is the general partner of WPX and WPXP. Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP LP"), is the general partner of WPX LP. WPP GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WP X GP LP. Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WP Partners GP"), is the general partner of WP Partners.
(continuation from footnote 3) Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WP Partners GP. Charles R. Kaye and Joseph P. Landy are each Managing General Partners of WP and may each be deemed to control the Warburg Pincus entities. Messrs. Kaye and Landy disclaim beneficial ownership of all shares held by the Warburg Pincus entities.
872,100 shares were sold by WP X Finance, and 27,900 shares were sold by WPXP, each in connection with the exercise of the underwriter's overallotment option pursuant to the Issuer's initial public offering of Common Stock.
11,821,446 of these shares are held by WP X Finance and 378,183 of these shares are held by WPXP.
5,462,731 of these shares are held by WP X Finance and 174,761 of these shares are held by WPXP.
5,721,152 of these shares are held by WP X Finance and 183,028 of these shares are held by WPXP.
WP X Finance exercised a warrant to purchase 1,071,902 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WP X Finance paid the exercise price on a cashless basis, resulting in the Issuer withholding 327,467 of the warrant shares to pay the exercise price and issued to WP X Finance the remaining 744,435 shares.
All of the shares subject to the warrant are fully exercisable as of the date hereof.
This warrant is held by WP X Finance.
WP X Finance exercised a warrant to purchase 1,074,072 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WP X Finance paid the exercise price on a cashless basis, resulting in the Issuer withholding 328,129 of the warrant shares to pay the exercise price and issued to WP X Finance the remaining 745,943 shares.
WPXP exercised a warrant to purchase 34,291 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WPXP paid the exercise price on a cashless basis, resulting in the Issuer withholding 10,476 of the warrant shares to pay the exercise price and issued to WPXP the remaining 23,815 shares.
This warrant is held by WPXP.
WPXP exercised a warrant to purchase 34,361 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WPXP paid the exercise price on a cashless basis, resulting in the Issuer withholding 10,498 of the warrant shares to pay the exercise price and issued to WPXP the remaining 23,863 shares.
These shares are held by WP X Finance.
These shares are held by WPXP.
These shares are comprised of 327,467 shares and 328,129 shares withheld by the Issuer pursuant to the net exercise of warrants, as detailed in footnotes (9) and (12).
These shares are comprised of 10,476 shares and 10,498 shares withheld by the Issuer pursuant to the net exercise of warrants, as detailed in footnotes (13) and (15).
Prior to conversion to Common Stock, these shares are comprised of 1,490,378 shares held by WPX Finance and 47,678 shares held by WPXP.